Capital Flowing Back into Cannabis Stocks (GWPH, CGC, MCTC, TCNNF)

Cannabis investors have been burnt by oversupply and a proliferation of pretenders over the past two years. But the sun is finally starting to come back out from behind those clouds over the past month, with many survivors starting to show signs of thriving in the post-purge world that now defines the space.

The pandemic has both helped and hurt. But the process of naturally thinning the herd has been a powerful factor in driving fresh momentum – the wheat has finally been separated from the chaff.

The remaining “winners” now can perhaps look forward to reaping the rewards of the powerful structural growth trend analysts still anticipate defining the future of this space over coming years as the legalization and mainstreaming trends remain in place. That offers up a very strong investment thesis for new money looking for high-growth opportunities in a washed out sector.

With that in mind, we present a few of the most interesting names for consideration: GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Canopy Growth Corp (NYSE:CGC), MCTC Holdings Inc (OTCMKTS:MCTC) aka Cannabis Global Inc. (OTCMKTS:MCTC), and Trulieve Cannabis Corp (OTCMKTS:TCNNF).



GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) just hit the wires with Q1 results after the market closed on Monday. Sales came in at $120.6 million, more than triple the numbers dropped in the year-ago quarter, blowing out analyst estimates (consensus $109.4 million).

The big driver was Epidiolex, an FDA approved CBD treatment for refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Net product sales for the drug totaled $116.1 million in Q1, with $106.1 million of this amount generated in the U.S.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) bills itself as a biopharmaceutical company that engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.

The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an FDA approved treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia.

The context for this announcement is a strong bid, with shares acting well over the past five days. Shares have powered higher over the past month, rallying roughly 11% in that time on strong overall action.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has been acting well over the past five days. Shares have powered higher over the past month, rallying roughly 11% in that time on strong overall action.


Canopy Growth Corp (NYSE:CGC) is one of the biggest and most geographically diversified players in the cannabis space, with operations in 12 countries across five continents. The company engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps.

It’s perhaps the biggest overall name in the space when it comes to a combination of producing and investing in the space, so it has to be near the top of any measure as far as benefitting from a shift whereby full-scale legalization in the US market is concerned.

According to its own materials, the company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.

One of its most important divestitures and strategic interests is Canopy Rivers Inc., a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. The company works collaboratively with Canopy Growth to identify strategic counterparties seeking financial and/or operating support.

CGC has had a rough past week of trading action, with shares sinking something like -12% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -8%.

Canopy Growth Corp (NYSE:CGC) generated sales of $123.8M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 61.5% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($2.3B against $418.3M).


MCTC Holdings Inc (OTCMKTS:MCTC), now doing business as Cannabis Global, Inc. (MCTC), is interesting as a more speculative play. The company is one of the very few plays in the cannabis space that is building vertically from a base driven by genuine IP. MCTC has a number of strong patents in process at the USPTO and looks set to become a leading play on the red hot edibles infusion theme.

That’s interesting enough. But the story just got more interesting because the company’s verticalization theme is continuing to build and now includes a serious play in the explosive California cannabis delivery marketplace with its announcement this morning of an LOI with Whisper Weed Delivery of Los Angeles, a leading California cannabis delivery services provider, wherein Cannabis Global will provide management services in exchange for fees equivalent to 51% of the profits derived from Whisper Weed’s cannabis delivery services throughout the entire greater Los Angeles regional marketplace.

“We continue to verticalize operations from an IP-driven base, stacking a core technology and R&D edge under growing manufacturing operations, and now we have added an essential piece of that puzzle: an established leadership position in cannabis home delivery in the largest municipal cannabis market in the world,” commented, Arman Tabatabaei, CEO of Cannabis Global. “Whisper Weed is cash-flow positive, profitable, and growing rapidly in terms of volume and end-market footprint. Our aggressive growth strategy continues to move forward ahead of schedule. And this expansion into the rapidly growing California cannabis delivery space is an integral part of that plan.”

We would also note that the cannabis delivery space, itself, is a $10 billion industry already, and growing by leaps and bounds due to embedded structural factors as well as the COVID-19 pandemic, and its stay-at-home impact.

This news comes on the heels of a deal with BudCars, another juggernaut in the California cannabis delivery space.

In addition, MCTC Holdings Inc (OTCMKTS:MCTC) also just announced that it is starting to commercialize breakthrough research on THC-V, a “Varin” cannabinoid with the potential to work as a weight-loss supplement. The company has patents pending there as well, and may soon have a virtual monopoly on that market.

Keep this one on the radar.

Trulieve Cannabis Corp (OTCMKTS:TCNNF) is one of the best performing stocks in the cannabis space over the past couple months, with shares more than doubling since mid-March on strong action. The stock is now trading well above its major moving averages and sits on gains over the past 18 months – that’s a rare trait for a pot stock these days.

The company engages in the cultivation, possession, distribution, and sale of medical cannabis in the United States.

It offers a suite of Trulieve branded products with approximately 125 SKUs, including nasal sprays, capsules, concentrates, syringes, and cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges.

Trulieve Cannabis Corp (OTCMKTS:TCNNF) distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as takes orders online and by phone for delivery. As of November 20, 2018, the company operated 21 dispensaries. Trulieve Cannabis Corp. is headquartered in Quincy, Florida.

The stock has been acting well over recent days, up something like 10% in that time.

Trulieve Cannabis Corp (OTCMKTS:TCNNF) managed to rope in revenues totaling $105.2M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 121.6%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($119.1M against $73.6M).

“This article is part of Networks. Read the Networks Disclaimer.”



GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Files Marketing Authorization Application For Epidiolex® In Europe

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has submitted its Marketing Authorization Application to the European Medicines Agency for Epidiolex® as adjunctive treatment for seizures related with Dravet syndrome and Lennox-Gastaut syndrome, two extremely treatment-resistant types of childhood-onset epilepsy.

The details

GW Pharmaceuticals has obtained Orphan Designations from the European Medicines Agency for Epidiolex for the cure of Dravet syndrome, LGS, and lately, West syndrome & Tuberous Sclerosis Complex. In October 2017, the company completed the filing of its rolling Epidiolex NDA to the United States FDA, also for seizures linked with Dravet syndrome and LGS. This NDA has been approved by the FDA for Priority Review.

Justin Gover, the CEO of GW Pharmaceuticals, expressed that this Marketing Authorization Application filing marks another key milestone for the Epidiolex plan and is a vital next step toward offering this prospective new treatment option internationally. The company is dedicated to making Epidiolex available to people in Europe that fight with the burden of living with Dravet syndrome and LGS, both extremely difficult to cure and devastating conditions. They continue to establish a commercial infrastructure in Europe in expectation of future approval and release.

The MAA filing for Epidiolex is supported by report from three Phase III efficacy and safety trials, each of which fulfilled their primary objective. Epidiolex was usually well tolerated in these studies. The MAA comprises safety data on around 1,500 patients, with around 400 people on continuous therapy for over one year. Around 26% of the people suffering from Epidiolex from the Phase III pivotal plan came from European sites. Beyond pivotal efficacy and safety data, the MAA comprises a comprehensive clinical pharmacology, toxicology and pre-clinical package.

In unrelated news, the GW Pharmaceuticals posted that the U.S. FDA has accepted its filing for Priority Review of its New Drug Application for Epidiolex®. The PDUFA goal date for FDA completion is June 27, 2018.


Can GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Move Towards North?

In the last trading session, the stock price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) closed marginally in green, indicating that the stock may attempt to recoup its last week losses. Earlier in October, the company reported that it has closed the rolling submission of a NDA to the USFDA for Epidiolex® as adjunctive treatment targeting seizures associated with LGS and Dravet syndrome. This task was closed along with the help of company’s subsidiary unit – Greenwich Biosciences.

The details

GW Pharmaceuticals has been granted with Rare Pediatric Disease as well as Orphan Drug Designations from the USFDA for Epidiolex in the treatment of Dravet syndrome and LGS. Additionally, it has been given Fast Track Designation from the USFDA for Epidiolex for the cure of Dravet syndrome. Justin Gover, the Chief Executive Officer of GW Pharmaceuticals, expressed that the filing of the Epidiolex NDA is a significant achievement for people suffering with LGS and Dravet syndrome.

This indicates that there is a potentially new treatment option in horizon for these two difficult to treat and grave conditions. On behalf of company’s employees, patients and clinicians, who have been a part of the Epidiolex plan, they are pleased to file the NDA for this promising therapy for U.S. FDA review. The team look forward to offer every support to the FDA throughout the assessment course. This regulatory submission is an indication of GW’s commitment to developing unique cannabinoid-based treatments. The company is currently assessing additional clinical development plans in other orphan seizure disorders.

The NDA for Epidiolex goes with on the back of data from three Phase III safety and efficacy trials, each of which achieved their main endpoint. GW Pharmaceuticals intends to file a Marketing Authorization Application in Europe for Epidiolex in the imminent future. Epidiolex is a pharmaceutical formulation of purified CBD, which is in development for the cure of numerous rare childhood-onset epilepsy ailments.


SinglePoint, Inc (OTCMKTS:SING) Directs Its Efforts To Accelerating Growth In Cannabis Sector

The stock of SinglePoint, Inc (OTCMKTS:SING) closed at $0.073 losing 8.25% in yesterday’s trading session. This provider has recently been seen to pay much focus to accelerated growth in Cannabis sector and it targets to make its impact felt globally.

One of its greatest moves has been the signing of a letter of intent in which it expressed its interest towards the acquisition of Dr. FeelGood. This is a rather profitable medical marijuana distribution that has for pretty long indicated its commitment to setting up a proprietary delivery and ordering technology. SinglePoint remains optimistic that the new acquisition will help towards boosting it revenue stream.

The provider is confident of closing this acquisition soon and that will give a proper demonstration of the company’s ability to develop its portfolio of investments in established high-growth, high-potential cannabis enterprises. Earlier this year, this company succeeded in the acquisition of some two companies and asserts that the latest acquisition will be a significant addition to its portfolio.

SinglePoint CEO, Greg Lambrecht opined, “We are well capitalized to continue acquisitions and we are optimistic to complete around three more acquisitions and significantly increase the company’s revenue.”

He added that the company was in a better position, something that they have been looking forward to for quite long.

The President of Dewmar International BMC Inc (OTCMKTS:DEWM), J.D. Houston has expressed his willingness to attend the upcoming conference. The MJAC 2017 will be providing the various retail investors with a perfect opportunity to access crucial business insight on firms in the cannabis sector.

The shareholders that will be attending the meeting will learn much regarding Dewmar’s cannabis business setup from revenue generating services and products to portfolio of IP assets. The president is also expected to have a word with managers of micro-cap funds who have indicated their interest towards investing in firms like Dewmar.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) recently gave its latest update on the Q3 2017 Financial Performance. The NDA filing procedure for Epidiolex is already up and running and most probably by October the final sections of the filing will be at the verge of completion.


The American Academy Of Neurology Releases Its Data Regarding Epidiolex® (Cannabidiol) As GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) publicizes the matter

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform.

The company through one of its top executives has come forward to make public American Academy of Neurology (AAN)’s issuance of the positive results associated with a second Phase 3 study (GWPCARE3) of Epidiolex® (cannabidiol or CBD) among adults and children as well who are struggling with Lennox-Gastaut syndrome (LGS).

According to some close sources, the data will most probably be presented during the forthcoming meeting linked with the American Academy of Neurology (AAN) situated in Boston, MA. The announcement from a speculative point of view is sure to put a smile on the faces of the large number of patients struggling with related complications.

As a matter of fact, the Lennox-Gastaut syndrome happens to be one of the trickiest types of epilepsy for medical experts to deal with. It was disclosed from the placebo-controlled research that indeed Epidiolex is observed to clinically provide significant reductions in an acceptable safety and tolerability profile in line with the seizure frequency.

According to one of the provider’s top executives, Epidiolex has the capacity to offer a positive change towards dealing with LGS .On that same note, he moved ahead to show his great excitement following the plans the company had put in place in the future prescriptions.

It goes without saying that what any top company needs to ensure is the setting up of a more standardized as well as a tested pharmaceutical formulation of cannabidiol. That will help a huge deal towards helping patients around the globe.

The trial set up revealed that indeed Epidiolex was from a general perspective well tolerated. However, the recent Phase 3 Study had showcased a pattern of some adverse events that had remained quite persistent over time.

It was a great thing that during a prestigious meeting there was the highlighting of the Phase 3 epilepsy program, and that the wide neurological community needed to pay closer attention as a matter of fact!


GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) CEO To Present At The Annual Healthcare Conference

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) CEO Justin Gover will present at the upcoming Cowen and Company Annual Healthcare Conference on March 8, 2017. Several new drugs and therapies are being advanced at a rapidly increasing pace in the Cannabidiol market such as the application of phytocannabinoids to avoid an array of numerous medical conditions and ailments.

As increasing number of states have approved medicinal marijuana applications in the United States and Canada, Cannabis firms involved in research and development activities in cannabinoid medicinal applications and clinical studies continue to move ahead despite the Federal indications of a likely crack down on recreational pot use.

Biotech and cannabis stocks with latest industry developments comprise GW Pharmaceuticals and many other firms like Earth Science Tech and Insys Therapeutics.

The buzz

GW Pharmaceuticals proclaims itself as a biopharmaceutical corporation that engages in discerning, advancing, and commercializing CBD prescription medicines. It works through three divisions: Sativex Research & Development and Pipeline R&D. The firm mainly offers Sativex, which an oromucosal spray for the cure of spasticity occurring as a side-effect to multiple sclerosis.

GW Pharmaceutical is also focused on the Phase 3 clinical development plan of Sativex for application in the cure of cancer pain; and Phase II studies in other indications, like neuropathic pain. Additionally, the firm’s product pipeline comprises Epidiolex, a cure for Lennox-Gastaut syndrome and Dravet syndrome, as well as other offerings in Phase I and II clinical advancement for the cure of glioma, type-2 diabetes, schizophrenia and adult epilepsy.

It has its work spread in the United Kingdom, Europe, Canada, Asia and the United States. The company was instituted in 1998 and is based in the United Kingdom.

In the last trading session, the stock price of GW Pharmaceuticals over 1% to close the session at $128.99. The market cap of firm stands at $2.81 billion.

Pin It on Pinterest